AbbVie's (ABBV) Atrasentan Receives Orphan Drug Designation
Tweet Send to a Friend
AbbVie (NYSE: ABBV) Atrasentan for treatment of pediatric nephrotic syndrome was granted an FDA Orphan Drug Designation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE